Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Expert Opin Biol Ther. 2008 Sep;8(9):1347-63. doi: 10.1517/14712598.8.9.1347 .

Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development.

Author information

  • 1National Cancer Institute, National Institutes of Health, Vaccine Branch, Bethesda, Maryland 20892-5065, USA.

Abstract

BACKGROUND:

In recent years the HIV vaccine field introduced a number of promising vaccine candidates into human clinical trials.

OBJECTIVE:

To briefly discuss the advances made in vaccine development and HIV pathogenesis and give an overview of the body of work our lab has generated in multiple animal models on replication-competent Adenovirus recombinant vaccines.

METHODS:

Emphasis is placed on comparative examination of vaccine components, routes of immunization and challenge models using replicating Adenovirus vectors.

RESULTS/CONCLUSION:

The findings make the case that replicating Adenovirus vectors are superior in priming multiple arms of the immune system, and in conjunction with protein boosting, have resulted in dramatic protective efficacy leading to their advancement to Phase I trials. Implications of the recent halting of the Merck Ad5-HIV Phase IIb clinical trial of our vaccine approach and other vectored vaccines are discussed.

PMID:
18694354
[PubMed - indexed for MEDLINE]
PMCID:
PMC2538611
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Informa Healthcare Icon for PubMed Central
    Loading ...
    Write to the Help Desk